Added to YB: 2024-05-31
Pitch date: 2024-05-29
IKNA [bullish]
Ikena Oncology, Inc.
-15.88%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
Market Cap
$69.0M
Pitch Price
$20.40
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.58
P/E
-2.24
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Ikena Oncology: 50% RIF, Trading Below Cash, Strategic Alternatives
IKNA: Shuttering IK-930 development, 53% workforce reduction (88% total), pursuing strategic alternatives. Another Ph1 asset IK-595 remains. $75M mkt cap vs $133M cash. Potential catalysts: new reverse merger rules, OrbiMed 23% stake, BMY collaboration remnants. Moving fast to cut costs.
Read full article (1 min)